NeuBase Therapeutics Appoints COO

NeuBase Therapeutics, Inc. has appointed industry veteran William Mann, Ph.D., MBA as chief operating officer. Dr. Mann will leverage his decades of experience in the biopharma industry to manage NeuBase operations and advance its strategic goals.

Most recently, he served as the president and chief executive officer of Helsinn Therapeutics (U.S.), Inc. Before joining Helsinn, he held multiple positions at Sapphire Therapeutics, Inc., rising to vice president of corporate development, where he was instrumental in the sale of the company to Helsinn in 2009. Bill began his professional career at Novartis, where he led a multidisciplinary drug discovery program and served as director of business development.

"Dr. Mann brings expertise gained through an impressive career working in the pre-clinical, clinical and commercial operational areas in top global pharmaceutical companies. Our goal with this important addition to our team is to ensure the infrastructure within the organization is structured for accelerated growth,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase. "The broad applicability of the PATrOL™ platform positions NeuBase to become a fully integrated dominant pharmaceutical company, and I look forward to working closely with Dr. Mann as we work to realize the full potential of our first-in-class transformative technology platform in addressing the root causes of a multitude of diseases.”